Literature DB >> 31115038

Impact of ruxolitinib on myelofibrosis patients post allogeneic stem cell transplant-a pilot study.

Jeffrey J Pu1,2,3, Joyson Poulose1, Jozef Malysz1, Junjia Zhu1, Julie C Fanburg-Smith1, David F Claxton1, Michael G Bayerl1.   

Abstract

Entities:  

Keywords:  allogeneic haematopoietic stem cell transplantation; myelofibrosis; ruxolitinib

Year:  2019        PMID： 31115038      PMCID： PMC6706301          DOI： 10.1111/bjh.15967

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  8 in total

Review 1.  Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group.

Authors:  N M Kröger; J H Deeg; E Olavarria; D Niederwieser; A Bacigalupo; T Barbui; A Rambaldi; R Mesa; A Tefferi; M Griesshammer; V Gupta; C Harrison; H Alchalby; A M Vannucchi; F Cervantes; M Robin; M Ditschkowski; V Fauble; D McLornan; K Ballen; U R Popat; F Passamonti; D Rondelli; G Barosi
Journal:  Leukemia       Date:  2015-08-21       Impact factor: 11.528

2.  Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations.

Authors:  M Marchetti; G Barosi; F Cervantes; G Birgegård; M Griesshammer; C Harrison; R Hehlmann; J-J Kiladjian; N Kröger; M F McMullin; F Passamonti; A Vannucchi; T Barbui
Journal:  Leukemia       Date:  2016-10-14       Impact factor: 11.528

3.  Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report.

Authors:  Ayalew Tefferi; Francisco Cervantes; Ruben Mesa; Francesco Passamonti; Srdan Verstovsek; Alessandro M Vannucchi; Jason Gotlib; Brigitte Dupriez; Animesh Pardanani; Claire Harrison; Ronald Hoffman; Heinz Gisslinger; Nicolaus Kröger; Juergen Thiele; Tiziano Barbui; Giovanni Barosi
Journal:  Blood       Date:  2013-07-09       Impact factor: 22.113

4.  Peritransplantation Ruxolitinib Prevents Acute Graft-versus-Host Disease in Patients with Myelofibrosis Undergoing Allogenic Stem Cell Transplantation.

Authors:  Nicolaus Kröger; Sharifah Shahnaz Syed Abd Kadir; Tatjana Zabelina; Anita Badbaran; Maximilian Christopeit; Francis Ayuk; Christine Wolschke
Journal:  Biol Blood Marrow Transplant       Date:  2018-05-22       Impact factor: 5.742

Review 5.  Primary myelofibrosis and its targeted therapy.

Authors:  Lindsey Shantzer; Kristin Berger; Jeffrey J Pu
Journal:  Ann Hematol       Date:  2016-08-19       Impact factor: 3.673

6.  Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease.

Authors:  Silvia Spoerl; Nimitha R Mathew; Michael Bscheider; Annette Schmitt-Graeff; Sophia Chen; Tony Mueller; Mareike Verbeek; Julius Fischer; Vera Otten; Martina Schmickl; Kristina Maas-Bauer; Jürgen Finke; Christian Peschel; Justus Duyster; Hendrik Poeck; Robert Zeiser; Nikolas von Bubnoff
Journal:  Blood       Date:  2014-04-07       Impact factor: 22.113

7.  Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.

Authors:  R Zeiser; A Burchert; C Lengerke; M Verbeek; K Maas-Bauer; S K Metzelder; S Spoerl; M Ditschkowski; M Ecsedi; K Sockel; F Ayuk; S Ajib; F S de Fontbrune; I-K Na; L Penter; U Holtick; D Wolf; E Schuler; E Meyer; P Apostolova; H Bertz; R Marks; M Lübbert; R Wäsch; C Scheid; F Stölzel; R Ordemann; G Bug; G Kobbe; R Negrin; M Brune; A Spyridonidis; A Schmitt-Gräff; W van der Velden; G Huls; S Mielke; G U Grigoleit; J Kuball; R Flynn; G Ihorst; J Du; B R Blazar; R Arnold; N Kröger; J Passweg; J Halter; G Socié; D Beelen; C Peschel; A Neubauer; J Finke; J Duyster; N von Bubnoff
Journal:  Leukemia       Date:  2015-07-31       Impact factor: 11.528

8.  Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study.

Authors:  Vikas Gupta; Heidi E Kosiorek; Adam Mead; Rebecca B Klisovic; John P Galvin; Dmitriy Berenzon; Abdulraheem Yacoub; Auro Viswabandya; Ruben A Mesa; Judith Goldberg; Leah Price; Mohamed E Salama; Rona Singer Weinberg; Raajit Rampal; Noushin Farnoud; Amylou C Dueck; John O Mascarenhas; Ronald Hoffman
Journal:  Biol Blood Marrow Transplant       Date:  2018-09-08       Impact factor: 5.742
  8 in total
  3 in total

Review 1.  Genomics of MPN progression.

Authors:  Anand A Patel; Olatoyosi Odenike
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

2.  Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance.

Authors:  Massimo Breccia; Francesca Palandri; Paola Guglielmelli; Giuseppe Alberto Palumbo; Alessandra Malato; Francesco Mendicino; Alessandra Ricco; Emanuela Sant'Antonio; Mario Tiribelli; Alessandra Iurlo
Journal:  Curr Oncol       Date:  2022-07-15       Impact factor: 3.109

Review 3.  60 Years Young: The Evolving Role of Allogeneic Hematopoietic Stem Cell Transplantation in Cancer Immunotherapy.

Authors:  Nicoletta Cieri; Katie Maurer; Catherine J Wu
Journal:  Cancer Res       Date:  2021-06-09       Impact factor: 12.701
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.